Epilepsy and Alzheimer's cell therapy biotech lays off 25% of staff
A Bay Area biotech working on off-the-shelf cell therapies for epilepsy, Alzheimer’s and other undisclosed indications laid off about 25% of its workforce recently, Neurona Therapeutics confirmed to Endpoints News.
The private biotech, launched eight years ago out of the labs of neuroscientists at UCSF, let 18 of its 68 employees go, a spokesperson wrote to Endpoints in an emailed statement. Most of the affected staffers were involved in research, the spokesperson added, noting the focus is on a clinical-stage asset, with preclinical programs paused.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.